FDA Plans to Expand Access to Certain OpioidsCommissioner Scott Gottlieb makes a departure from previous policy.
FDA alters stance on opioid addiction drugs
FDA alters stance on opioid addiction drugsFDA is advising that these 2 opioid addiction medications should not be withheld from patients taking benzodiazepines or other drugs that depress the central nervous system.
How Should Opioid Addiction Be Treated?As the opioid crisis worsens, debates rage about the best methods to combat it.
Insurer: No more prior auths for opioid addiction medsAs part of efforts to combat the opioid epidemic, Cigna removes prior authorization from medication-assisted treatment for opioid use disorder.
Four developments helping address the opioid epidemicAs the opioid epidemic continues across the U.S., new treatment programs and guidelines could help reverse the trend.
Pharmacists should get training in naloxone use nowPharmacists are the most accessible healthcare resource. Once trained in naloxone use, we can train our patients in all aspects of opioid use. This will make a difference.
Part1: Recognition and referral to enhance recovery: The pharmacist’s role in managing opioid use disorder
Part1: Recognition and referral to enhance recovery: The pharmacist’s role in managing opioid use disorderThe goal of this program is to enhance knowledge and awareness of opioid use disorder in order to identify and effectively manage patients at risk of overdose.
New HHS plan on opioids ups naloxone useHealth and Human Services (HHS) recently launched a widespread initiative – including increasing the use of naloxone to reverse opioid overdoses – aimed at reducing prescription opioid and heroin related overdose, death and dependence.
Critical error in methadone label, guidelinesAn error in the package insert and clinical guidelines may contribute to the high rates of patient harm associated with methadone.
Knowledge of MATs key to overcoming opioid abuse challengesThe biggest challenge in tackling opioid abuse is lack of awareness and understanding of addictive diseases, as well as misinformation and negative perceptions of medication-assisted therapies (MATs), according to a recent opinion article published in the New England Journal of Medicine.